title: Death of a clinical trial: a speculative inclusion criterion gone wrong.
authors.forename: M A
authors.initials: MA
authors.lastname: Rosenthal
authors.forename: H
authors.initials: H
authors.lastname: Woo
authors.forename: H
authors.initials: H
authors.lastname: Gurney
authors.forename: M
authors.initials: M
authors.lastname: Copeman
authors.forename: G
authors.initials: G
authors.lastname: Zingarelli
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001315:Australia; D017024:Chemotherapy, Adjuvant; D004164:Diphosphonates / Q000627:therapeutic use; D000077143:Docetaxel; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use; D008297:Male; D015337:Multicenter Studies as Topic; D009364:Neoplasm Recurrence, Local; D017430:Prostate-Specific Antigen / Q000097:blood; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000601:surgery*; D016032:Randomized Controlled Trials as Topic; D020133:Reverse Transcriptase Polymerase Chain Reaction; D043823:Taxoids / Q000627:therapeutic use; D000077211:Zoledronic Acid
chemical_list: D000970:Antineoplastic Agents; D004164:Diphosphonates; D007093:Imidazoles; D043823:Taxoids; D000077143:Docetaxel; D000077211:Zoledronic Acid; D017430:Prostate-Specific Antigen